CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy.
Protocol for the development of a bioluminescent AML-PDX mouse model for the evaluation of CAR T cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
急性髓系白血病患者来源异种移植(AML-PDX)模型能够保留患者样本的复杂性和异质性,较细胞系模型具有优势。本文介绍在小鼠中建立生物发光AML-PDX模型、用于评估嵌合抗原受体(CAR)T细胞疗法的实验方案。文章描述AML-PDX细胞转导、植入、扩增及富集的步骤,随后详述体外和体内验证AML-PDX模型、用于评估CAR-T 细胞免疫治疗的流程。该方案的完整使用和执行细节请参阅Caulier等人的研究。
Patient-derived xenograft (PDX) models of acute myeloid leukemia (AML-PDX) offer advantages over cell line models by capturing the complexity and heterogeneity of patient-derived samples.
Here, we present a protocol for developing a bioluminescent AML-PDX model in mice to evaluate chimeric antigen receptor (CAR) T cell therapy.
We describe steps for transducing, engrafting, expanding, and enriching AML-PDX cells.
We then detail procedures for in vitro and in vivo validation of the AML-PDX model for the evaluation of CAR T cell immunotherapy. For complete details on the use and execution of this protocol, please refer to Caulier et al. 1 .
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。